Scholars Central

Conference abstractPublished 7 Dec 2015

Review of Virus-Like Particle Production, Characterization & Comparability for Contemporary Vaccines

Authors: Michael W. Washabaugh

MedImmune, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Viral diseases offer a major challenge to vaccine development because of the complex nature of virus structures and the large size of the virus particle needed to generate an effective immune response. Classical approaches to develop antiviral vaccines have required the use of attenuated (or inactivated) live viruses produced in cell culture. Although this approach has been widely successful and is still in practice, not all viruses are amenable to replication in cell culture, particularly at commercial scale. In appropriate expression systems, recombinant viral proteins of modest size (24 kDa) have been produced that self-assemble into icosahedral virus-like particles (VLPs) whose surface is immunochemically comparable to that of the actual virus – this has been a major success story in contemporary vaccines. This talk reviews the scientific challenges in the production and characterization of VLP vaccines, and the data necessary to provide assurance of comparability for manufacturing changes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectInfectious Diseases
  • SubjectPhysics & Astronomy
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Michael W. Washabaugh”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels